articleTop 1% cited

Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB–IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial

The Lancet Oncology · 2006 · Vol. 7(9) · pp. 719–727

Jean‐Yves Douillard✉(Centre d'Investigation Clinique de Nantes)Rafael Rosell(Institut Català d'Oncologia)Mario De Lena(Istituti di Ricovero e Cura a Carattere Scientifico)Francesco Carpagnano(Ospedale San Paolo)Rodryg Ramlau(Instytut Gruźlicy i Chorób Płuc)J.L. González-Larriba(Hospital Clínico San Carlos)Tomasz Grodzki(University of Szczecin)José Rodrigues Pereira(Instituto do Câncer do Estado de São Paulo)A. Le Groumellec(Centre hospitalier Bretagne Atlantique)Vito Lorusso(Ospedale Antonio Cardarelli)C. ClaryAntonio J. Torres(Hospital Clínico San Carlos)Jabrail Dahabreh(Sismanoglio General Hospital)Pierre‐Jean Souquet(Hôpital Lyon Sud)Julio Astudillo(Hospital Universitari Germans Trias i Pujol)P. Fournel(Hôpital Nord)Á. Artal(Hospital Universitario Miguel Servet)Jacek JassemLeona KoubkováPatricia His(Pierre Fabre (France))M Riggi(Pierre Fabre (France))P Hurteloup(Pierre Fabre (France))

View via DOI Publisher page

Lung Cancer Diagnosis and Treatment Lung Cancer Treatments and Mutations Lung Cancer Research StudiesMedicineVinorelbineInternal medicineHazard ratioNeutropeniaLung cancerChemotherapyClinical endpointFebrile neutropeniaSurgery

MeSH terms

VinorelbineAdolescentAdultAgedAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Non-Small-Cell LungCisplatinFemaleHumansLung NeoplasmsMaleMiddle AgedNeoplasm StagingVinblastineSurvival Rate

Citations

1,580

FWCI

74.05

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group